Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 13/20 | 0.37 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | PLTP | P55058 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5545492 | 0.92 | AOC3 (0.40) | AOC3 | |
| SCHEMBL5545483 | 0.92 | AOC3 (0.40) | AOC3 | |
| SCHEMBL5551582 | 0.90 | AOC3 (0.47) | AOC3 | |
| SCHEMBL4988537 | 0.87 | AOC3 (0.41) | AOC3 | |
| SCHEMBL4990208 | 0.85 | AOC3 (0.42) | AOC3 | |
| SCHEMBL4871878 | 0.85 | AOC3 (0.42) | AOC3 | |
| SCHEMBL5545451 | 0.84 | AOC3 (0.39) | AOC3 | |
| SCHEMBL5550201 | 0.83 | AOC3 (0.39) | AOC3CSNK2A2CSNK2BCSNK2A1DYRK1A | |
| SCHEMBL4991267 | 0.82 | PPARA (0.42) | AOC3CSNK2A2CSNK2BCSNK2A1DYRK1A | |
| SCHEMBL3931989 | 0.81 | AOC3 (0.39) | AOC3CSNK2A2CSNK2BCSNK2A1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254931-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | ASTELLAS PHARMA INC. (JP) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254931-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | VCAM1, VAPB, VAPA | AOC3 386/4885CSNK2A2 3888/4885CSNK2B 3900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.